Devender Dhanda - Bristol Myers Squibb Co

基本信息

浏览量：0

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 72 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Real World Outcomes of Older Adults and Frail Patients with Relapse/Refractory Multiple Myeloma Receiving Idecabtagene Vicleucel

Othman Salim Akhtar,Hamza Hashmi,Temitope Oloyede,Ruta Brazauskas, Matthew Bye,Surbhi Sidana,Doris K Hansen,Nausheen Ahmed,Christopher Ferreri,Aimaz Afrough,Larry D. Anderson,Binod Dhakal,Devender Dhanda,Lohith Gowda,Melanie Harrison,Amani Kitali,Heather J Landau,Abu-Sayeef Mirza, Dr. Jinalben Patel,Pallavi Patwardhan

Transplantation and Cellular Therapyno. 2 (2024): S184-S185

引用0浏览0引用

P-044 External Control Analysis for KarMMa-3: Idecabtagene Vicleucel (Ide-Cel) Vs Real-World Standard of Care (RW SoC; COTA) for Triple-Class Exposed (TCE) Relapsed/Refractory Multiple Myeloma (RRMM)

Hans Lee,Kevin Towle,Shannon Cope, Sichen Liu, Jenny Chen,Sundar Jagannath,Sikander Ailawadhi,Thomas Marshall, Teofilia Acheampong,Devender Dhanda

Clinical Lymphoma Myeloma and Leukemia (2024): S66-S67

引用0浏览0引用

P-033 External Control Analysis for KarMMa-3: Idecabtagene Vicleucel (Ide-Cel) Vs Real-World Standard of Care (RW SoC; Connect MM) for Triple-Class Exposed (TCE) Relapsed/Refractory Multiple Myeloma (RRMM)

Sundar Jagannath,Harlan Campbell,Julie Park,Jenny Chen,Kevin Towle,Shannon Cope,Brian Durie,Hans Lee,Sikander Ailawadhi, Rafat Abonour,Robert Rifkin,Howard Terebelo,Mohit Narang,Cristina Gasparetto,Kathleen Toomey, James Hardin,Thomas Marshall,Edward Yu,Liang Liu,Devender Dhanda

Clinical Lymphoma Myeloma and Leukemia (2024): S59-S60

引用0浏览0引用

Administering Selected Subscales of Patient-Reported Outcome Questionnaires to Reduce Patient Burden and Increase Relevance: a Position Statement on a Modular Approach

Daniel Serrano,David Cella,Don Husereau,Bellinda King-Kallimanis,Tito Mendoza,Tomas Salmonson,Arthur Stone,Alexandra Zaleta,Devender Dhanda,Andriy Moshyk, Fei Liu,Alan L. Shields,Fiona Taylor, Sasha Spite,James W. Shaw,Julia Braverman

QUALITY OF LIFE RESEARCHno. 4 (2024): 1075-1084

引用0浏览0WOS引用

P-045 Idecabtagene Vicleucel (Ide-Cel) in Patients (pts) with Clinical High-Risk Early Relapse Multiple Myeloma (MM) Without Front-Line (1L) Autologous Stem Cell Transplantation (ASCT): KarMMA-2 Cohort 2B

Xavier Leleu,Alfred Chung,Noopur Raje, Meera Mohan,Reuben Benjamin,Adam Sperling, Larry Anderson,Madhav V. Dhodapkar, Shambavi Richard,Anna Truppel-Hartmann,Sarah Johnston, Fan Wu,Debashree Basudhar,Ethan Thompson,Devender Dhanda,Laurie Eliason, Sinhan Tran, Maria Chaudhry,Melissa Alsina

Clinical Lymphoma Myeloma and Leukemia (2024): S67

引用0浏览0引用

Implementing Multi-Level Network Meta-Regression for Time-to-event Outcomes: A Case Study in Relapsed Refractory Multiple Myeloma

Dylan Maciel,Jeroen P. Jansen,Sven L. Klijn,Kevin Towle,Devender Dhanda,Bill Malcolm,Shannon Cope

VALUE IN HEALTH（2024）

引用0浏览0WOS引用

A Review of Meaningful Change Thresholds for EORTC QLQ-C30 and FACT-G Within Oncology

Nathan A. Clarke,Julia Braverman, Gill Worthy,James W. Shaw,Bryan Bennett,Devender Dhanda,Kim Cocks

Value in Healthno. 4 (2024): 458-468

引用0浏览0WOS引用

PCR209 Joint Modeling of Progression-Free Survival (PFS) and Patient-Reported Symptoms among Relapsed/Refractory Multiple Myeloma (RRMM) Patients

S. Knop, H. Einsele,D. Dhanda, T. Marshall,L. Eliason, D. McLoone,C. Caisip, J. Chen, D. Boehm,A. D. Dhamane, K. Ramasamy,S. Cope,K. Towle

Value in Healthno. 6 (2024): S335-S335

引用0浏览0引用

Analysis of Patient-Reported Experiences Up to 2 Years after Receiving Idecabtagene Vicleucel (Ide-Cel, Bb2121) for Relapsed or Refractory Multiple Myeloma: Longitudinal Findings from the Phase 2 KarMMa Trial

Michel Delforge,Paula Rodriguez Otero,Nina Shah,Olga Moshkovich,Julia Braverman,Devender S. Dhanda,Sally Lanar,Jennifer Devlen,Matthew Miera,Heather Gerould,Timothy B. Campbell,Nikhil C. Munshi

Leukemia Research (2023)

引用0浏览0WOS引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn